Pulse Ox + Auscultation Reliable for Congenital Heart Screening

Share this content:
Pulse Ox + Auscultation Reliable for Congenital Heart Screening
Pulse Ox + Auscultation Reliable for Congenital Heart Screening

FRIDAY, Sept. 22, 2017 (HealthDay News) -- Pulse oximetry (POX) plus cardiac auscultation is a reliable method for neonatal congenital heart disease screening, according to a study published online Sept. 22 in Pediatrics.

Xiao-jing Hu, Ph.D., from the Children's Hospital of Fudan University in Shanghai, and colleagues assessed the accuracy of POX plus cardiac auscultation for the detection of major congenital heart disease (CHD) in 15 Chinese hospitals (July 1, 2012, through Dec. 31, 2014). An abnormal POX or cardiac auscultation was defined as screen positive. Echocardiograph was performed on all screen-positive newborns.

The researchers found that the hospital screening rate ranged from 94.0 to 99.8 percent, with 167,190 consecutive asymptomatic newborn infants screened. In total, 203 screened newborns had major CHD (44 critical and 159 serious). The sensitivity of POX plus cardiac auscultation was 95.5 percent for critical CHD and 92.1 percent for major CHD, with false-positive rates of 1.2 and 1.1 percent, respectively.

"We show that using POX plus cardiac auscultation significantly improved the detection rate of major CHD in the early neonatal stage, with high sensitivity and a reasonable false-positive rate," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Doctors Urged to Speak With Patients About Firearms

Doctors Urged to Speak With Patients About Firearms

Making a public commitment is encouraged as a positive action that physicians can take

Machine Learning Model Predicts Risk of Upgrade to Breast CA

Machine Learning Model Predicts Risk of Upgrade to ...

Model can predict risk of upgrade of high-risk breast lesions to cancer using traditional, text features

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Glycemic Control Up With Oral Semaglutide in Type ...

Phase 3 studies next to assess longer-term/clinical outcomes, safety

is free, fast, and customized just for you!

Already a member?

Sign In Now »